REG - Cambridge Cognition - PTSD trials with top 10 pharma company & US DoD

Cambridge Cognition HoldingsAnnouncement

28/07/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220728:nRSb9994Ta&default-theme=true

RNS Number : 9994T  Cambridge Cognition Holdings PLC  28 July 2022

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition wins PTSD trials with top 10 pharmaceutical company

and the United States Department of Defense

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce two
agreements in a new therapeutic area for the Company, post-traumatic stress
disorder ("PTSD").  Most recently, a research agreement was entered into with
the with the United States Department of Defense, following on from a contract
secured earlier this year with a top 10 pharmaceutical company.
Approximately 20 PTSD treatment trials run every year(1), demonstrating the
potential for further sales in this therapeutic area.

 

PTSD affects around 15 million adults a year(2) and up to 31% of veterans,
many of whom do not experience relief from their symptoms with existing
medications. It has been suggested that the symptoms of PTSD could directly
lead to deficits in executive functioning, including re-experiencing
memories, problems with concentration, and hyperarousal interrupting working
memory performance(3).

 

Only two pharmacological treatments for PTSD have received FDA-approval. One
reason for this could be that drug response is highly variable between
affected individuals, making it difficult to develop effective treatments. In
efforts to address the therapeutic need, the United States Department of
Defense is developing a precision medicine approach to PTSD. Cambridge
Cognition has been selected as a cognitive assessment provider for the project
because CANTAB(TM) offers accurate measurement of the potentially distinct
pathophysiological processes involved in PTSD.

 

Pharmaceutical companies are also investigating the potential for new drug
classes for PTSD.  Recently, a top 10 pharmaceutical company has contracted
with Cambridge Cognition to be their cognitive assessment partner for an
upcoming PTSD treatment trial. In delivering the contract, Cambridge Cognition
will provide its proprietary cognitive assessment tool, CANTAB(TM), as an
exploratory endpoint.

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"Cognitive impairment is increasingly recognised as a major component of
PTSD.  At Cambridge Cognition, we are pleased to be providing the company's
expertise to monitor cognitive symptoms with a view to improving outcomes for
those suffering from the after-effects of major trauma."

 

For further information, contact:

 

 Cambridge Cognition Holdings Plc                      Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer
 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)  Tel: 020 7886 2968

 Freddy Crossley / Emma Earl                           (Corporate Finance)

 Rupert Dearden                                        (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)                Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)                Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

References

1.    TrialTrove search of PhI - IV PTSD Trials 2011 - 2021

2.    US Department of Veteran Affairs.
https://www.ptsd.va.gov/understand/common/common_adults.asp
(https://www.ptsd.va.gov/understand/common/common_adults.asp)

3.    Vasterling, J. J., Duke, L. M., Brailey, K., Constans, J. I., Allain,
A. N., Jr., & Sutker, P. B. (2002). Attention, learning, and memory
performances and intellectual resources in Vietnam veterans: PTSD and no
disorder comparisons. Neuropsychology, 16, 5-14.

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZGZNLNKGZZM